Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Conditions

Arthritis, Rheumatoid 8Psoriasis 7Lymphoma, Follicular 4Leukemia 4Myelodysplastic Syndromes 3Asthma 3Vasculitis 2Respiratory Distress Syndrome 2Recurrence 2Pneumonia 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Inflammation 2Granulomatosis with Polyangiitis 2Bronchiolitis Obliterans 2Arthritis, Psoriatic 2Arthritis, Juvenile 2Wilms Tumor 1Uveitis 1Temporomandibular Joint Disorders 1Spondylitis, Ankylosing 1Spondylarthritis 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms 1Metabolic Syndrome 1

Interventions

Etanercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Granulomatosis with Polyangiitis × Etanercept × Clear all
NCT00001901 2008-03-04

Etanercept to Treat Wegener's Granulomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
60 enrolled

Vasculitis, Granulomatosis with Polyangiitis

NCT00005007 2007-12-28

Etanercept for Wegener's Granulomatosis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Phase 2/3 Completed
181 enrolled

Vasculitis, Granulomatosis with Polyangiitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡